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Abstract
Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clinical features such as
anemia, lytic bone lesions, hypercalcemia, and renal disease. An enhanced understanding of MM disease
mechanisms has led to new more targeted treatments. There is now a plethora of treatments available for MM. In
this review article, our aim is to discuss many of the novel agents that are being studied or have recently been
approved for the treatment of MM. These agents include the following: immunomodulators (pomalidomide),
proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors
(afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat,
rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies
(daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors.
Keywords: Multiple myeloma, Novel agents, Immunomodulators, Proteasome inhibitors, Alkylating agents, AKT
inhibitors, BTK inhibitors, CDK inhibitors, HDACIs, IL-6 inhibitors, Kinesin spindle protein inhibitors, Monoclonal
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Background
Multiple myeloma (MM) is the second most common
hematologic malignancy and accounts for as many as
20 % of deaths from hematological malignancies and 2 %
of deaths from all cancers. In 2012, there were an esti-
mated 89,658 people living with myeloma in the USA.
Approximately 0.7 % of men and women will be diag-
nosed with myeloma during their lifetime, based on the
2010–2012 data. The median age at diagnosis is 65 years,
and 5-year survival is 46.6 % [1]. MM may result from
the generation and proliferation of malignant plasma cell
clones from germinal center lymphocytes, a process that
is driven by multiple factors including interleukin 6
(IL-6) and tumor necrosis factor (TNF) alpha. In some in-
stances, MM is a consequence of the malignant transform-
ation of post-germinal center plasma cells, via a proposed
two-step model of progression [2]. In the first step,
an abnormal response to antigenic stimulation foments
limited clonal proliferation and precipitates the premalig-
nant entity of monoclonal gammopathy of undetermined
significance (MGUS). A “second hit,” such as dysregula-
tion of cell cycle controls, escapes from normal apoptotic
pathways, or a change in the stromal microenvironment,
then stimulates the malignant clonal proliferation which
characterizes MM. Upon its initial transformation from
MGUS, MM often enters a quiescent, or “smoldering,”
phase characterized by a relatively measured rate of clonal
expansion and the absence of overt clinical symptoms [3].
As the clonal burden becomes substantial, however, dys-
functional plasma cells both directly infiltrate organs and
cause indirect damage via the mass production of mono-
clonal light chains. The resulting outcome is characterized
by its wide-ranging and manifold presentations including,
but not limited to, anemia, renal failure, bony involve-
ment, hypercalcemia, weight loss, fatigue, and any com-
bination therein [4]. MM is a heterogeneous disease, with
its wide spectrum of aggression and treatment resistance
likely the result of the various genetic errors and a diverse
array of malignant cellular malfunctions, which drive indi-
vidual clones [5]. Whereas some patients may live a dec-
ade or more following diagnosis, others suffer rapid
treatment resistant progression and die within 24 months.
In spite of recent progress in the development of new and
increasingly effective agents, MM remains an incurable
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disease, which in its end stages is characterized by rapid
relapse and broad treatment refractoriness [6, 7].
The past decade has seen extraordinary advances in
the treatment of symptomatic MM, particularly with the
advent of proteasome inhibitors (such as bortezomib)
and immunomodulatory agents (such as lenalidomide),
which have become the pillars of frontline treatment
regimens [8]. Newly symptomatic patients generally re-
spond well to their first line of treatment and enter a
period of remission characterized by stable and effective
control of symptoms. As there is no curative treatment,
MM inevitably relapses, though it does respond to add-
itional lines of frontline treatment approximately 50 %
of the time [7]. Subsequent relapses then occur with in-
creasing frequency and become increasingly refractory
to frontline agents. It is during that phase of disease that
novel investigational agents enter clinical use as part of
clinical trials [9]. Initial treatment strategies depend on the
patient’s ability to tolerate intensive treatment. Younger pa-
tients (typically those younger than 65) with relatively little
comorbidity are treated with high-dose chemotherapy and
autologous stem cell transplant (ASCT), whereas older pa-
tients, with more formidable comorbidities, receive more
moderately dosed chemotherapy only [10]. A decade ago,
vincristine-doxorubicin-dexamethasone (VAD) was among
the foremost induction regimens; however, it has since
been supplanted by bortezomib- and lenalidomide-based
regimens, which offer markedly improved response rates at
comparable toxicity. Three drug regimens featuring borte-
zomib, dexamethasone, and an additional agent (typically
cyclophosphamide or lenalidomide) are now the standard
of care prior to ASCT [11]. The standard conditioning
regimen for ASCT is currently melphalan based (Mel200)
[8]. A number of trials are presently ongoing to assess the
effectiveness of post-ASCT consolidation regimens and es-
tablish optimal consolidation standards; however, consen-
sus exists that consolidation therapies should remain brief,
with the intent to deepen response while minimizing added
toxicity. Following induction, transplant, and consolidation,
maintenance therapy is pursued with the goal of prolong-
ing response, delaying progression, and improving overall
survival. However, the use of frontline agents in each of
these treatment stages has resulted in 5-year survival rates
as high as 80 % [8]. Nevertheless, in the absence of a true
cure, malignant plasma cell clones do, over time, become
increasingly aggressive and increasingly refractory to even
frontline treatments, prompting relapse, progression, and
death. It is in the arena of such relapsed and refractory dis-
ease that novel agents enter into investigational use [12].
Clinical trials, both completed and ongoing, point to
an emerging generation of agents which are active in re-
lapsed and refractory myeloma and which may someday
form part of an expanded front line. Indeed, some
among these novel agents (including pomalidomide,
carfilzomib, ixazomib, daratumumab, elotuzumab, and
panobinostat) have already been granted FDA approval
in the relapsed/refractory setting [9]. The forthcoming
generation of therapies will include proteasome inhibitors
(marizomib and oprozomib); histone deacetylase inhibi-
tors; kinesin spindle protein inhibitors; and inhibitors of
cyclin-dependent kinase (CDK), IL-6, Bruton’s tyrosine
kinase (BTK), B cell lymphoma 2 (Bcl-2), protein kinase
B (AKT), and phosphoinositide 3-kinase (PI3K) path-
ways in addition to array of monoclonal antibodies and
repurposed alkylating agents. These agents are designed
based on our breadth of knowledge regarding malig-
nant plasma cell transformation, proliferation, survival,
and clonal expansion. At present, their development
statuses run the gamut from preclinical studies to phase
3 trials, to approved clinical use in the relapsed/refrac-
tory setting [8, 12].
Pathophysiology
The sentinel events in the oncogenesis of a malignant
plasma cell clone take place in the germinal center, most
likely during the mutation-prone processes of isotype class
switching and somatic hypermutation [13]. Although
these initial mutations may generate a malignant clone,
they are typically regarded as necessary but not sufficient
for myeloma oncogenesis. The next pathogenic events,
where the original clone terminally differentiates into a
malignant plasma cell, are thought to take place in the
bone marrow [14]. Indeed, the bone marrow microenvir-
onment has been proposed as a key determinant of the
progression from pre-myeloma states to malignant disease
[15]. The bone marrow niche has been demonstrated to
encourage tumor proliferation, resistance to apoptosis,
and cancer cell trafficking. In this niche, the premalignant
clone takes part in the array of cytokine-mediated cross
talk which characterizes the bone marrow milieu and in-
cludes a diverse set of resident cells including bone mar-
row stem cells, mesenchymal stem cells, osteoblasts,
osteoclasts, vascular endothelial cells, fibroblasts, adipo-
cytes, monocytes, T cells, and NK cells. The cytokines and
soluble factors generated in this neoplastic microenviron-
ment promote clonal proliferation and downregulate
apoptotic pathways, while providing greater opportunity
for additional oncologically potentiating mutations.
Soluble factors generated in the bone marrow niche
which have been shown to induce and promote malignant
transformation and proliferation include insulin growth
factor 1 (IGF-1), IL-6, IL-12, IL-15, Wnt3A, platelet-
derived growth factor receptor (PDGFR), vascular endothe-
lial growth factor (VEGF), TNF-α, and numerous others
[2, 5, 16]. Among the most studied of these cytokines is
IL-6, which is chiefly produced by bone marrow stem
cells and macrophages and is an important mediator of
myeloma cell growth, survival, migration, and drug
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resistance [17]. IL-6 is essential to the survival and
propagation of both normal and pathologic plasma cells
and has been shown to be a required factor for mye-
loma clones [18]. Myeloma cell lines have been found
to have increase expression of the IL-6 receptor, and in-
hibition of IL-6 has been found to impede myeloma
growth [19]. IL-6 is a product of bone marrow stromal
cells and acts as a paracrine stimulus for plasma cells.
Plasma cell adhesion to bone marrow stroma has been
shown to increase stromal IL-6 secretion, thus leading
to a self-augmenting feedback loop and demonstrating
how amplification of IL-6 pathways may be central to
plasma cell tumorigenesis [20]. Indeed, IL-6 has been
shown to be a powerful promoter of plasma cell sur-
vival and inhibitor of plasma cell apoptosis via numer-
ous pathways including upregulation of Bcl-xL and
Mcl-1 [21]. Other cytokines in the bone marrow micro-
environment may promote myeloma survival and
growth via promotion of local angiogenesis (upregula-
tion of VEGF), evasion of cell-mediated immunity
(downregulation of TNF-α and IL-12), promotion of
clonal proliferation, and escape from apoptotic path-
ways (upregulation of PDGF and IGF-1) [2, 5, 12, 16].
The cumulative effect of this cytokine environment is
to alter the balance of pro-apoptotic and anti-apoptotic
forces within the nascent myeloma cells, favoring un-
regulated clonal expansion and malignant proliferation.
These cytokines and soluble factors all provide poten-
tial rational targets for drug design.
Classifications
Two major systems exist for staging MM: the Inter-
national Staging System (ISS) and the Durie-Salmon sta-
ging system. The ISS is the preferred system due to its
simplicity and objectivity. In the ISS, patients are stratified
into three categories based on their serum beta-2-
microglobulin and albumin levels. Stage I disease is de-
fined as a B2M <3.5 mg/L and serum albumin ≥3.5 g/dL.
Stage III disease is defined as a B2M ≥5.5 mg/L. Stage II
disease is defined as meeting the requirements for neither
stage I nor stage III disease [22].
Prognostic factors
Prognosis for patients with myeloma is contingent upon
multiple factors, some of which are patient specific (age,
performance status, comorbidities) and some of which
relate to the specific genetic and cellular characteristics
of the plasma cell clone. Methods of genetic and cellular
phenotyping may be used to stratify myeloma into vari-
ous risk levels based on the presence or absence of a
number of known clone-specific features. Common find-
ings on FISH and karyotyping include t(11;14), t(6;14),
t(4;14), t(14;16), t(14;20), del 17p13, trisomies of odd-
numbered chromosomes, deletions of chromosome 13,
and hypodiploidy. In general, the detection of trisomies
portends a better prognosis, and such patients are
termed “low-risk.” In general, t(14;16), t(14;20), or del
17p13 portend a poorer prognosis and are regarded to
be “high-risk.” These patients account for approximately
15 % of cases and have a median survival of 2 to 3 years
with standard treatment. Patients with t(4;14), deletion
13, or hypodiploidy have “intermediate-risk” disease. Pa-
tients who lack any of the above abnormalities are “stand-
ard-risk” disease [23]. There are a number of other
significant characteristics to guide us in establishing the
prognosis of MM patients. For instance, high levels of
serum beta-2 microglobulin are associated with greater
tumor burden and—therefore—poorer prognosis. Plasma
cell clones that are more immunophenotypically similar to
normal reactive plasma cells likely suggest a better prog-
nosis compared to those with a more abnormal immuno-
phenotype [24]. Similarly, a more abnormal free-light-
chain (FLC) ratio may confer a poorer prognosis as may
the specific type of monoclonal protein produced [25].
Established treatments
Patients eligible for ASCT are treated with induction ther-
apy for up to 4 months before stem cell harvesting.
Regimens for induction for standard-risk patients in-
clude proteasome inhibitor-based regimens such as
cyclophosphamide/bortezomib/dexamethasone (CyBorD)
and immunomodulator-based regimens such as lenali-
domide/bortezomib/dexamethasone (RVD) [26, 27]. The
decision between proteasome inhibitor and immuno
modulator-based regimens is driven by specific drug avail-
ability, patient comorbidities, cost, and patient preference
[26]. Patients ineligible for ASCT should still be evaluated
for induction with lenalidomide, bortezomib, or an
alkylating agent-based regimen [28, 29]. Patients with
high-risk disease are often enrolled in clinical trials at the
outset of treatment, as prognosis is poor with conven-
tional regimens. High-risk patients unable to enroll in tri-
als often receive induction regimens, which feature
both a proteasome inhibitor and immunomodulator such
as RVD. Eligible patients then continue on to ASCT with
bortezomib-based or lenalidomide maintenance therapy
thereafter at times [30, 31]. Patients are evaluated for re-
sponse following each treatment cycle. A small number of
patients will prove refractory to initial treatment, and
majority of the patients will eventually relapse following
initial treatment. ASCT-eligible patients who did not re-
ceive ASCT with initial treatment should be treated with
high-dose chemotherapy followed by ASCT at the time of
relapse. Patients having already undergone ASCT and
demonstrated a significant response may be treated with
repeat ASCT or chemotherapy alone at the time of relapse
[32]. MM that relapses more than 1 year after initial treat-
ment will typically respond well to a repeated course of
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the same initial treatment. If relapse occurs sooner, a
different treatment regimen will be required [33]. Specific
regimens for relapsed and refractory disease are based on
available agents such as bortezomib, thalidomide, lenalido-
mide, carfilzomib, pomalidomide, alkylating agents,
anthracyclines, and corticosteroids, administered alone, or
more often as components of two or three agent combina-
tions. Patients with MM relapsed or refractory to multiple
frontline therapies should be considered for enrollment in




Pomalidomide is a novel anti-myeloma agent that be-
longs to the immunomodulatory class. Pomalidomide
acts both on myeloma cells and their stromal support
systems in the bone marrow microenvironment, to in-
hibit both intracellular and extracellular myeloma
growth mediators. Pomalidomide exerts its immuno-
modulatory effects by priming natural killer cells and
constraining regulatory T cells, thus weakening immune
tolerance of myeloma cells and spurring the cellular
immune response against them. The effects of pomalido-
mide may be partially mediated by cereblon, a protein
involved in intracellular ubiquitination pathways. Pre-
clinical studies demonstrated that pomalidomide was
active against lenalidomide- and bortezomib-resistant
cell lines and that its effects were synergistic with
dexamethasone [36].
Pomalidomide has been studied extensively and dem-
onstrated impressive results in the treatment of relapsed
and refractory MM. In the first such phase 2 trial, 60 re-
lapsed/refractory patients were treated with pomalido-
mide and low-dose dexamethasone, with 63 % of the
patients achieving a confirmed response. Responses were
seen in 40 % of the lenalidomide refractory patients,
37 % of the thalidomide refractory patients, 60 % of the
bortezomib refractory patients, and 74 % of the patients
with high-risk cytogenetic or molecular markers. Median
progression-free survival was 11.6 months [37]. In a trial
investigating pomalidomide and low-dose dexametha-
sone in specifically lenalidomide refractory patients, a
cohort of 34 such patients demonstrated an overall
response rate of 47 % with a median overall survival
of 13.9 months [38]. In another phase 2 study, 84 patients
refractory to both lenalidomide and bortezomib were
enrolled (with a median of 5 prior lines of treatment)
and showed a 35 % overall response to pomalidomide
and dexamethasone with a median overall survival of
14.9 months and 44 % survival at 18 months [39].
Studies investigating the efficacy of pomalidomide
with and without dexamethasone as well as pomalido-
mide with high-dose and low-dose dexamethasone
have demonstrated superior results with pomalidomide
and low-dose dexamethasone [40, 41].
Pomalidomide has demonstrated a relatively tolerable
safety profile with the most common grade 3/4 toxicities
being hematologic (neutropenia, anemia, and pancyto-
penia) and infectious events. Pomalidomide has demon-
strated an increased risk for venous thromboembolism,
and concurrent use of VTE prophylaxis has been recom-
mended [41]. In February 2013, pomalidomide was ap-
proved by the FDA, for use alone or in combination
with dexamethasone, in relapsed/refractory MM patients
who have received at least two prior therapies including
lenalidomide and bortezomib and have demonstrated
disease progression within 60 days of their most recent
treatment. Trials are in progress, which combine poma-
lidomide/dexamethasone with various other agents in-
cluding cyclophosphamide, clarithromycin, pegylated
liposomal doxorubicin, and proteasome inhibitors [42].
Proteasome inhibitors
Carfilzomib
The proteasome is the ultimate destination for ubiquiti-
nated proteins marked for degradation and clearance
from the intracellular space. In this way the proteasome
acts as a regulator of cytoplasmic protein expression.
Proteasome inhibition prompts the accumulation of mis-
folded and ubiquitinated intracellular debris and prevents
the degradation of pro-apoptotic factors, thus promoting
programmed cell death. Malignant cells, which depend
heavily on the suppression of apoptotic pathways, are
particularly sensitive to this interruption of routine
proteolysis. The proteasome has also been shown to
regulate intracellular levels of the anti-apoptotic pro-
tein NF-kB that is constitutively present in the cytosol
and inactivated by the IkB family inhibitors. When
phosphorylated, IkB is targeted for degradation by the 26S
proteasome, allowing translocation of NF-kB into the
nucleus. Proteasome inhibition increases the availability of
IkB within the cytosol, thus inhibiting NF-kB and
impairing one of the anti-apoptotic mechanisms of
NF-kB-dependent tumor clones [43–45].
Bortezomib, the forerunner of its class and potent in-
hibitor of the 26S proteasome, has become a frontline
agent in the treatment of MM since its approval by the
FDA in 2003. Carfilzomib, the most prominent of the
novel proteasome inhibitors, irreversibly binds the 20S
proteasome, preventing its chymotrypsin-like activity
and promoting the accumulation of pro-apoptotic polyu-
biquitinated proteins, resulting in cell cycle arrest, pro-
grammed cell death, and inhibition of tumorigenesis. In
vitro studies have demonstrated that carfilzomib is a
more specific inhibitor of chymotrypsin-like proteolysis
at the proteasome than bortezomib and has fewer off
target effects. These preclinical observations have been
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followed by clinical data demonstrating the relatively
more benign toxicity profile of carfilzomib, most signifi-
cantly its lower association with peripheral neuropathy.
Even more encouraging has been the seemingly weak
and incomplete cross-resistance between bortezomib
and carfilzomib, a promising finding for bortezomib re-
fractory patients [44, 45].
Single-agent carfilzomib has demonstrated significant
efficacy in relapsed/refractory MM. Two hundred sixty-
six patients, 95 % of whom were refractory to their most
recent therapy and 80 % of whom were either refractory
to or intolerant to both bortezomib and lenalidomide,
demonstrated an overall response rate of 23.7 % with a
median duration of response and median overall survival
of 7.8 and 15.6 months, respectively. Common adverse
events included fatigue (49 %), anemia (46 %), nausea
(45 %), and thrombocytopenia (39 %). Only 12.4 % of
patients experienced peripheral neuropathy [43]. It was on
the strength of this phase 2 study that carfilzomib ob-
tained its initial FDA approval for the treatment of
relapsed/refractory myeloma. It is presently approved
for use in patients who have received at least two
prior therapies, including bortezomib and an immu-
nomodulatory agent, and have demonstrated disease
progression within 60 days of completing their most
recent therapy [45, 46].
In the ASPIRE trial, 792 patients with relapsed MM
were randomized to either carfilzomib with lenalidomide
and dexamethasone or to lenalidomide and dexametha-
sone alone. The addition of carfilzomib was found to sig-
nificantly improve progression-free survival to 26.3 months
in the carfilzomib group versus 17.6 months in the control
group (HR = 0.69, CI 0.57 to 0.83, p = 0.0001). Overall re-
sponse rate (ORR) in the carfilzomib group was 87.1 %
compared to 66.7 % in the control group, and the complete
response (CR) rate with carfilzomib was 31.8 % compared
with 9.3 % among controls. The adverse event rate
was similar in the two groups; however, patients in
the carfilzomib group reported superior health-related
quality of life [45].
ENDEAVOR was a phase 3 trial and directly compared
bortezomib to carfilzomib in relapsed MM patients.
Nine hundred twenty-nine patients, whose disease had
relapse after at least one but no more than three prior
treatment regimens, were randomized to either carfilzo-
mib with low-dose dexamethasone or bortezomib with
low-dose dexamethasone. Based on preliminary analysis
of interval outcomes, carfilzomib has demonstrated clear
clinical superiority with regard to the primary endpoint
of progression-free survival (PFS). Median PFS in the
carfilzomib and bortezomib groups at the time of the
most recent cutoff were 18.7 and 9.4 months, respect-
ively (HR = 0.53, 95 % CI 0.44–0.65). Furthermore, neur-
opathy rates were found to be significantly lower in the
carfilzomib group. The study results were presented at
the American Society of Clinical Oncology 2015 Annual
Meeting showing ORRs as 76.9 % in the carfilzomib arm
versus 62.6 % (p < .0001) in the bortezomib arm. Add-
itionally, 54.3 % (carfilzomib) versus 28.6 % (bortezomib)
had a very good partial response (PR) or better, and 12.5
versus 6.2 % of the patients had a complete response or
better. Treatment discontinuation due to an adverse
event (AE) occurred in 14.0 % in the carfilzomib arm
and 15.7 % of the patients in the bortezomib arm.
Overall survival data were immature and continue to
be followed [46, 47].
Carfilzomib is also being evaluated as a potential in-
duction agent for newly diagnosed MM. In a phase 2
trial of carfilzomib with cyclophosphamide and dexa-
methasone, in elderly patients with newly diagnosed
MM, the regimen induced high CR rates and was associ-
ated with low toxicity [48]. Fifty-eight patients were
treated with carfilzomib/cyclophosphamide/dexametha-
sone followed by carfilzomib maintenance until progres-
sion or intolerance with 95 % of the patients achieving
at least a PR (including 71 % with at least a very good
partial response (VGPR), 49 % with at least near CR,
and 20 % with stringent CR). The most frequent toxic-
ities were neutropenia (20 %) and anemia (11 %) with
relatively few cases of mild peripheral neuropathy (9 %).
A similar trial examined cyclophosphamide, carfilzomib,
thalidomide, and dexamethasone (CYCLONE) in 64 pa-
tients with newly diagnosed MM, with 91 % of the patients
demonstrating at least a PR and 59 % demonstrating at
least a VGPR [49]. Stem cell collection was successful in all
patients in whom it was attempted with PFS and OS at
24 months found to be 76 and 96 %, respectively. Carfilzo-
mib has also been demonstrated to be an effective induc-
tion agent in combination with melphalan and prednisone
among transplant-eligible patients. Toxicities were found
to be manageable and peripheral neuropathy rare [50].
Ixazomib
Ixazomib is an inhibitor of the 20S proteasome and the
first oral proteasome inhibitor to enter clinical trials
[51]. Preclinical studies have demonstrated that ixazomib
is active in bortezomib-resistant cell lines and that its ef-
fects are synergistic with lenalidomide and dexametha-
sone [51]. A phase 1 trial of ixazomib that enrolled 60
patients with relapsed/refractory MM demonstrated
manageable toxicities (thrombocytopenia, diarrhea, nau-
sea, fatigue, and vomiting being the most prominent)
with a 20 % incidence of all peripheral neuropathy and
2 % incidence of grade 3 peripheral neuropathy. Eighteen
percent of the heavily pretreated cohort achieved PR or
better [51]. A similar phase 1 study, which also enrolled
60 patients, demonstrated similar toxicities and a 12 %
overall incidence of neuropathy. Fifteen percent of these
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heavily pretreated patients achieved PR or better with
76 % of patients achieving stable disease or better [52]. A
phase 1/2 study investigating the combination of ixa-
zomib, lenalidomide, and dexamethasone in patients
with newly diagnosed MM enrolled 65 patients. Fifty-
eight percent of the patients were found to have very
good PR or better [53]. These results were followed
by the TOURMALINE-MM1 phase 3 trial, a random-
ized, double-blind, placebo controlled clinical study of
722 patients evaluating ixazomib plus lenalidomide
and dexamethasone compared to placebo plus lenalido-
mide and dexamethasone in adult patients with relapsed
and/or refractory MM. The study showed a PFS of 20.6 in
the ixazomib arm versus 14.7 months in the control arm
(p = 0.012). ORR was 78.3 % in the ixazomib arm with me-
dian duration of response was 20.5 months, versus 71.5 %
and 15 months in the control arm. Median PFS in high-
risk patients was similar to that in the overall patient
population and in standard-risk patients. The most
common grade ≥3 adverse events in the ixazomib group
included neutropenia, anemia, thrombocytopenia, and
pneumonia [54]. The FDA granted ixazomib (trade name
Ninlaro) approval in November 2015 based on the result
of this study. Ninlaro is approved for use in combination
with lenalidomide and dexamethasone to treat MM pa-
tients who have received at least one prior therapy.
Marizomib
Marizomib is an investigational proteasome inhibitor,
which has been shown to irreversibly bind to all three
catalytic subunits of the 20S proteasome [55]. Marizomib’s
irreversible binding to the 20S proteasome and its signifi-
cantly lower rate of efflux from malignant cells appear to
account for its increased cytotoxicity and longer duration
of action, as well as its vigorous activity in bortezomib-
resistant cell lines. Phase 1 studies, though limited to date,
have demonstrated relatively mild toxicities and no evi-
dence of neuropathy or thrombocytopenia. In a dose es-
calation study of 15 relapsed/refractory myeloma patients
treated with marizomib monotherapy, three patients, all
of whom were bortezomib resistant, demonstrated at least
PR. Marizomib has demonstrated in vitro synergy with a
number of other anti-myeloma agents including immuno-
modulators and histone deacetylase inhibitors. Further-
more, because marizomib and bortezomib are structurally
dissimilar, and influence different apoptotic signaling
pathways, there exists strong rationale for using the two
agents in combination, especially given in vitro studies
demonstrating encouraging synergy [55, 56].
Oprozomib
Oprozomib is a structural analog of the 26S proteasome
inhibitor carfilzomib, which, unlike carfilzomib, is orally
bioavailable [57]. Oprozomib is only 20 % as potent as
carfilzomib, however, demonstrates similar cytotoxicity
with longer exposure as a result of its time-dependent
proteasome inhibition [58]. Phase 1 studies have demon-
strated a tolerable safety profile with low incidence of
neuropathy [57]. Twenty-nine patients with relapsed/re-
fractory MM were enrolled in a dose escalation study of
oprozomib/dexamethasone combination therapy. The
primary challenges to tolerability proved gastrointestinal
with frequent diarrhea, nausea, and vomiting. However,
none of the enrolled patients demonstrated new or
worsening of baseline neuropathy [59]. Preliminary re-
sponse rates in several phase 1 studies of heavily pre-
treated patients have been encouraging though sample
sizes remain small [57, 59, 60].
Monoclonal antibodies
Daratumumab
Daratumumab is a human IgG1k monoclonal antibody
against CD38, a cell surface protein that is prominently
expressed on myeloma cells and plays numerous roles in
myeloma tumorigenesis. CD38 is a regulator of cell adhe-
sion and likely helps mediate a favorable stromal environ-
ment for myeloma cells. As a regulator of intracellular
calcium signaling, CD38 is involved in the messenger
pathways which regulate apoptosis, survival, and prolifera-
tion. In addition, CD38 mediates cross talk with B cells, T
cells, and NK cells and may thus be a factor in immune
tolerance of malignant plasma cells. Finally, binding of
daratumumab to CD38 has been shown to mediate
phagocytosis of MM cells by macrophages [61, 62].
A phase 1/2 trial investigated the efficacy of daratumu-
mab with lenalidomide among 32 patients with relapsed
and refractory MM. The ORR in this heavily pretreated
population was found to be 88 %, with VGPR found
among 53 % of patients. Neutropenia was the most com-
monly encountered adverse event occurring among 81 %
of patients [63]. After demonstrating promise in com-
bination with lenalidomide, daratumumab was investi-
gated as a single agent in relapsed/refractory myeloma.
Seventy-two heavily pretreated patients were enrolled.
Thirty patients received scheduled doses of daratumu-
mab at 8 mg/kg while the remaining 42 patients received
scheduled doses of 16 mg/kg. Seventy-nine percent of
the patients enrolled had disease refractory to their most
recent line of treatment, including 64 % of patients re-
fractory to both bortezomib and lenalidomide. The most
common grade 3 or 4 adverse events were pneumonia
and thrombocytopenia. No dose-limiting toxicities were
reported. Daratumumab monotherapy demonstrated en-
couraging efficacy in this exceptionally refractory popu-
lation, with better response noted in the 42 patients that
received the higher dose (16 mg/kg). The ORR was 36 %
in the cohort that received 16 mg/kg (15 patients had
PR or better, 2 had VGPR, and 2 had CR) and 10 % in
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the cohort that received 8 mg/kg (3 patients had PR). In
the cohort that received 16 mg/kg, the median PFS was
5.6 months and 65 % of the patients who had a response
did not have progression at 12 months [64].
Seeking to build on the promise of the above studies, a
phase 2 trial is presently investigating daratumumab
monotherapy in MM patients with at least three lines of
prior therapy or double refractory disease. One hundred
six heavily pretreated (with a median of 5 previous lines
of therapy), poly-refractory (95 % refractory to the most
recent proteasome inhibitor and immunomodulatory
drug used) patients were enrolled at the time of the
most recent cutoff. Adverse events were fatigue (39.6 %),
anemia (33.0 %), nausea (29.2 %), thrombocytopenia
(25.5 %), back pain (22.6 %), neutropenia (22.6 %), and
cough (20.8 %). Five patients (4.7 %) discontinued treat-
ment due to adverse events. ORR was 29.2 % with a 7.4-
month median duration of response. Median time to
progression was 3.7 months. Median overall survival has
not been reached and the estimated 1-year OS rate is
65 %. After a median follow-up of 9.4 months, 14 out of
31 (45.2 %) responders remain on therapy [65].
A pooled analysis of 148 patients treated with daratu-
mumab monotherapy at a dose of 16 mg/kg, including
those patients in the above trials, lends further support
to the agent’s use in relapsed/refractory disease. The
pooled population had received a median of 5 prior lines
of treatment, and 86.5 % were double refractory. ORR
was 31.1 % among this heavily pretreated and extensively
refractory population. The median duration of response
was 7.6 months, median PFS was 4.0 months, and
overall survival was 20.1 months [66]. Given this well-
demonstrated efficacy in a population with limited estab-
lished treatment option, daratumumab is fast making in-
roads into the MM treatment paradigm. In November
2015, the FDA granted accelerated approval for daratumu-
mab (Darzalex) to treat MM patients who have received
at least three prior treatments [67]. More recently, and
based on the strength of the above trial data, daratumu-
mab was approved under accelerated assessment by the
European Medicines Agency for treatment of MM pa-
tients who are refractory to both proteasome inhibitors
and immunomodulatory agents. Along with elotuzumab,
daratumumab is the first monoclonal antibody approved
for the treatment of MM and demonstrates significant
promise for treatment of relapsed and refractory disease.
Elotuzumab
CS1, a subunit of CD2, is a cell surface glycoprotein and
member of the signaling lymphocyte activation molecule
(SLAM) family. CS1 is consistently expressed by MM
cells and rarely expressed in other tissues including
hematopoietic elements. The role of CS1 in the patho-
genesis of MM is unclear; however, it remains a rational
target for novel therapies. Elotuzumab is a humanized
IgG1 monoclonal antibody against CS1. Preclinical studies
demonstrated activity against MM which was synergistic
with proteasome inhibitors and immunomodulatory
agents. Phase 1 trials demonstrated the tolerability of
elotuzumab and provided preliminary indications of
its clinical efficacy. The most commons adverse event
was infusion reaction (present in 27–71 % of patients
in phase 1 trials) which was typically preventable with
premedication prior to infusion. The most common
grade 3/4 adverse events were hematologic, most
often lymphopenia [68].
While a phase 1 trial of elotuzumab monotherapy in
35 relapsed refractory patients demonstrated no object-
ive response, trials with combination therapy have
proved more encouraging [107]. A phase 1 study of
elotuzumab with bortezomib in 28 relapsed/refractory
patients yielded an ORR of 48 %, and a similar study
of elotuzumab with lenalidomide yielded an ORR of
82 % [68]. A phase 2 study of 73 relapsed/refractory
lenalidomide naïve patients treated with lenalidomide,
dexamethasone, and either low- or high-dose elotuzumab
yielded an encouraging response as well. ORR was 84 %
across all patients, 92 % in the low-dose cohort and 76 %
in the high-dose cohort. Median PFS was not reached in
the low-dose group and was 18.6 months in the high-dose
group, with a median follow-up of 20.8 months [68]. Thus,
elotuzumab demonstrated significant efficacy in this
relapsed/refractory population, though treatment at
the lower dosage proved more effective than treatment at
the higher dosage. Elotuzumab in combination with
bortezomib and dexamethasone was evaluated among
152 patients with relapsed/refractory MM. Patients
were randomized to receive either bortezomib/dexa-
methasone alone or in combination with elotuzumab.
The elotuzumab group demonstrated a median PFS of
9.7 months compared to 6.9 months among the control
group, yielding a hazard ratio (HR) of 0.72. VGPR or bet-
ter occurred in 36 % of patients in the elotuzumab group
compared with 27 % in the control group. Addition of elo-
tuzumab did not seem to add clinically significant toxicity
to the treatment regimen [69].
Building on the strength of the above early-phase
trials, the first phase 3 trial of elotuzumab in MM,
the ELOQUENT 2 trial, included 646 relapsed/refractory
patients randomized to receive elotuzumab plus lenalido-
mide/dexamethasone versus lenalidomide/dexamethasone
alone. The primary end points were PFS and ORR. At
1 year, PFS in the elotuzumab and the control groups was
68 and 57 %, respectively, and at 2 years, PFS was 41 and
27 % respectively. Median PFS was 19.4 months in
the elotuzumab group and 14.8 months in the control
group. Addition of elotuzumab to lenalidomide and
dexamethasone carried a hazard ratio of 0.70 (CI 0.57
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to 0.85, p < 0.01) for progression or death. ORR was
79 % in the elotuzumab group and 66 % in the con-
trol group (p < 0.001) [70]. Accordingly, elotuzumab
(Empliciti) was granted FDA approval in November
2015 for relapsed/refractory MM patients in combination
with lenalidomide and dexamethasone. Elotuzumab and
daratumumab are the first monoclonal antibodies ap-
proved for use in MM and herald the rise of immuno-
therapy to a position of prominence in the myeloma
treatment paradigm. An additional phase 3 trial, ELO-
QUENT 1, comparing elotuzumab with lenalidomide/
dexamethasone to lenalidomide/dexamethasone alone
among patients with previously untreated MM is cur-
rently ongoing.
Indatuximab
Indatuximab is a chimerized anti-CD138 monoclonal
antibody conjugated to the maytansinoid cytotoxin
DM4, a potent inhibitor of the microtubule assembly
[71]. CD138 is a relatively exclusive plasma cell marker,
with minimal expression among other hematopoietic lin-
eages. CD138 expression is considerably upregulated in
MM cells, as well as in other hematologic, solid, and
neuroendocrine tumors. Overexpression of CD138 on
malignant plasma cells is substantial and makes it
among the most specific target antigens for MM. Conju-
gation of anti-CD138 to DM4 allows for the targeted de-
livery of cytotoxins to myeloma cells. Indatuximab is
internalized at the cell surface, releasing DM4 into the
cytoplasm where its anti-tubulin effects promote cell
death [71]. Preclinical studies have demonstrated consid-
erable synergy between indatuximab and lenalidomide,
prompting the design of a phase 1/2a trial investigating
indatuximab-lenalidomide-dexamethasone among re-
lapsed/refractory patients [72]. Fifteen patients were
enrolled, of whom 87 % had prior lenalidomide exposure
and 50 % were lenalidomide/dexamethasone refractory.
The patients were divided into low-, intermediate-, and
high-dose groups with respect to indatuximab. The most
common adverse events were fatigue, hypokalemia, and
diarrhea, and two patients withdrew due to toxicity. ORR
was 78 % with all non-responders achieving disease
stabilization [72]. The study was insufficiently powered
to detect dose dependence but showed the potentials of
indatuximab in the treatment of refractory/relapsed
MM patients.
SAR (SAR650984)
Like daratumumab, SAR650984 is a monoclonal anti-
body to CD38. SAR650984 exerts anti-tumor activity
via antibody-dependent cell-mediated cytotoxicity,
complement-dependent cytotoxicity, direct apoptosis
induction, and allosteric inhibition of CD38 enzymatic ac-
tivity [73]. In a phase 1 dose escalation trial, 35 patients
with heavily pretreated relapsed myeloma received
SAR650984. SAR650984-related adverse events (grade 3/4)
included pneumonia (n = 3), with hyperglycemia, hypopho-
sphatemia, pyrexia, apnea, fatigue, thrombocytopenia, and
lymphopenia in one patient each. ORR was 24 % and CR
was 6 %. In the subset of patients treated at higher dose
levels (n = 18), ORR was 33 % and CR was 11 % without a
significant increase in adverse events [73]. An additional
phase 1 trial investigated the combination of SAR650984
and lenalidomide in 31 heavily pretreated and relapsed pa-
tients. There were no dose-limiting toxicities. The most
common adverse events were fatigue (41.9 %), nausea
(38.7 %), upper respiratory tract infection (38.7 %), and
diarrhea (35.5 %). Infusion-associated reactions occurred in
38.7 % of patients and prompted treatment discontinuation
in 2 patients. ORR was 64.5 % and clinical benefit response
(CBR) was 71 %. Among patients relapsed and refractory
to both immunomodulatory agents and proteasome inhibi-
tors (n = 21), ORR was 52.4 % and CBR was 61.9 %. Me-
dian PFS among all patients was 6.2 months. Among
patients pretreated with proteasome inhibitors or immuno-
modulators, median PFS was 4.8 months [74].
Histone deacetylase inhibitors
Panobinostat
Histone acetylation and deacetylation plays important
roles in the regulation of gene expression [75]. In gen-
eral, hyper-acetylated chromatin is transcriptionally ac-
tive, and hypo-acetylated chromatin is transcriptionally
silent. Altering the acetylation of chromatin may thus
alter the expression of oncogenes and tumor suppressors
and thus influence both oncogenesis and play a role in
rational drug design. The histone deacetylase (HDAC) 6
has been shown to serve an additional function, as an
acetylator and regulator of the aggresome protein deg-
radation pathway. HDAC6 inhibition blocks aggresome
formation, thus inhibiting the degradation of misfolded
proteins and causing their accumulation within cells.
This both echoes and interrelates with the proposed
mechanism of proteasome inhibition, which is character-
ized by the prevention of ubiquitinated protein degradation
within the proteasome and explains the observation
of synergy between histone deacetylase inhibitors and
proteasome inhibitors [75]. Panobinostat is an oral
pan-deacetylase inhibitor, which increases the acetylation
of proteins involved in numerous oncogenic pathways,
including the abovementioned aggresome protein degrad-
ation pathway. Preclinical studies demonstrated that in-
hibition of the aggresome pathway by panobinostat, when
combined with inhibition of the proteasome pathway by
bortezomib, resulted in synergistic cytotoxicity among
MM cells [76].
The PANORAMA 2 trial evaluated the combination of
panobinostat and bortezomib along with dexamethasone
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in patients with relapsed and bortezomib refractory
MM. Fifty-five heavily pretreated patients with a median
of four prior regimens and two prior bortezomib-
containing regimens were enrolled. ORR was found to
be 34.5 %; clinical benefit rate was 52.7 % and median
PFS was 5.4 months. The most common adverse events
were thrombocytopenia (64 %) followed by fatigue and
diarrhea [76]. In a phase 3 randomized double blinded
study (PANORAMA 1 trial), patients with relapsed or
refractory MM received bortezomib, dexamethasone,
and either panobinostat or placebo. A total of 768 heavily
pretreated patients were randomized in that trial. The pri-
mary endpoint, PFS, was 12 months in the panobinostat
group and 8.1 months in the placebo group (p < .0001; HR
0.63, 95 % CI (0.52, 0.76)). Discontinuation of treatment
due to adverse events occurred in 36 % of patients in the
panobinostat group and 20 % of patients in the placebo
group. Patients in the panobinostat group proved consid-
erably more likely to demonstrate thrombocytopenia
(67 vs 31 %), neutropenia (35 vs 11 %), and diarrhea
(26 vs 8 %) [77]. Given the strength of the above tri-
als, the FDA approved panobinostat (under the trade
name Farydak) in February 2015, in combination with
bortezomib and dexamethasone, for treatment of MM
patients who have received at least two prior standard
therapies (including bortezomib and an immunomod-
ulatory agent) [78].
Ricolinostat
Ricolinostat (ACY-1215) is an HDAC6-specific histone
deacetylase inhibitor. The combination of ricolinostat
with the novel proteasome inhibitor carfilzomib has
demonstrated synergistic toxicity to myeloma cells re-
sistant to bortezomib in the preclinical setting [79].
Proteasome inhibition was shown to precipitate the
accumulation of misfolded and ubiquitinated proteins
within the aggresome, and HDAC6 inhibition was shown
to disrupt proper aggresome formation and function [79].
The resulting mass aggregation of ubiquitinated intracel-
lular detritus, with no available mechanism for disposal,
prompted activation of apoptotic pathways. Similar syner-
gistic effects have been demonstrated with ricolinostat
and other proteasome inhibitors [80]. Murine models of
MM have demonstrated significant delay in tumor growth
and significant prolongation of survival when treated with
combination of ricolinostat and bortezomib [80].
Vorinostat
Vorinostat is an orally bioavailable, non-specific histone
deacetylase inhibitor. It was approved by the FDA in
2006 for the treatment of cutaneous T cell lymphoma
and has shown activity in other hematologic and non-
hematologic malignancies as well [81]. Phase 1 studies in
patients with MM demonstrated a modest side effect
profile and suggested promising activity in combined
regimens [82–84]. VANTAGE 095 was a phase 2b trial
of vorinostat and bortezomib in bortezomib refractory
patients who were either refractory, ineligible, or intoler-
ant to immunomodulator-based regimens [85]. One
hundred forty-three heavily pretreated patients, all of
whom had received prior treatment with both bortezo-
mib and an immunomodulator, were enrolled. ORR, the
primary endpoint, was 17 % in this population of borte-
zomib refractory patients, with a clinical benefit rate of
31 % and a median duration of response of 6.3 months
[86]. VANTAGE 088 was a phase 3 trial comparing bor-
tezomib and vorinostat to bortezomib and placebo in
patients with non-refractory MM (patients with known
resistance to bortezomib were excluded from the study)
[81]. Three hundred seventeen patients were included in
the vorinostat group and 320 in the placebo group. PFS
was the primary endpoint and was 7.63 months in the
vorinostat group versus 6.83 months in the placebo
group (p = 0.01). Incidence of thrombocytopenia was
considerably higher in the vorinostat group (45 vs 24 %)
while other toxicities were comparable [81]. Vorinostat
may thus be a salvage option in patients that are refrac-
tory to bortezomib and immunomodulators; however, its
effect in bortezomib-sensitive patients, although signifi-
cant, is of unclear practical clinical utility [87].
Alkylating agents
Bendamustine
Bendamustine is a well-known alkylating agent initially
developed in the 1960s, which has more recently been
under increasing investigation for its potential utility in
the treatment of MM [88]. Bendamustine acts as a
classical alkylating agent of the nitrogen mustard class
by inducing cell cycle arrest and promoting apoptosis
via the alkylation of DNA [88]. Recent trials have
demonstrated the efficacy of bendamustine, in com-
bined regimens, among broader cohorts of myeloma
patients, and in particular among those with relapsed
and/or refractory disease [89].
The combination of bendamustine, lenalidomide, and
dexamethasone (BLD) has been shown to be safe and ef-
fective in patients with relapsed or refractory MM. A
multicenter phase 1/2 trial with a total of 29 enrolled re-
lapsed/refractory patients treated with BLD demon-
strated a PR rate of 52 %, with very good PR achieved in
24 %, and minimal response in an additional 24 % of pa-
tients. One-year OS was 93 %, and median PFS was
6.1 months with 1-year PFS of 20 %. Grade 3/4 adverse
events were largely hematologic including neutropenia,
thrombocytopenia, and anemia [90]. The combination of
bendamustine with bortezomib and dexamethasone has
also been shown to be an active and well-tolerated regi-
men in patients with relapsed or refractory myeloma.
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This combination was evaluated in 79 relapsed refractory
patients. The primary endpoint, ORR, was 60.8 %. PFS
was 9.7 months and OS was 25.6 months. The most
common adverse events were again hematologic [91]. An
additional trial of combination bendamustine-bortezomib-
dexamethasone, in this instance investigating its use as a
second-line treatment among elderly patients at the time
of relapse, has also demonstrated encouraging results. A
total of 73 (median age 76 years) patients were enrolled
with the primary end point being overall response rate
(ORR). ORR assessed during treatment was 69.8 %. A total
of 57.6 % of patients achieved at least PR. A complete re-
sponse was seen in 10.9 % of the patients, a very good par-
tial response (VGPR) in 16.5 %, and a PR in 29 39.7 %
[92]. Bendamustine has also been investigated, in combin-
ation with thalidomide and dexamethasone, as a salvage
option in relapsed and/or refractory myeloma patients to
both bortezomib and lenalidomide. In a retrospective
analysis of 30 such double refractory patients treated
with the bendamustine-thalidomide-dexamethasone
combination, 87 % achieved stable disease or better.
At a median follow-up time of 12.1 months, median
PFS and overall survival were 4.0 and 7.2 months, re-
spectively. The most common grade 3–4 adverse events
were again hematological toxicities [93]. Numerous phase
1 and 2 clinical trials are now underway to investigate the
combination of bendamustine with carfilzomib and
dexamethasone in relapsed/refractory patients, as well
as the combination of bendamustine, melphalan, and




AKT is a protein kinase central to many of the signaling
pathways, which guide cellular proliferation and apop-
tosis. Elevated expression of AKT has been demon-
strated in myeloma cell lines as well as in bone marrow
aspirates form patients with MM. High levels of acti-
vated AKT have been revealed in the plasma cells of
myeloma patients, with significantly lower levels found
in the plasma cells of patients with smoldering myeloma,
and lower levels still in those patients with monoclonal
gammopathy of unknown significance. Myeloma cell
lines subjected to AKT downregulation via small inter-
fering RNA have demonstrated significantly increased
rates of apoptosis. Given these findings, AKT seemed to
be a rational target in the treatment of MM. The most
notable headway to date has been made with the ATP-
competitive AKT inhibitor afuresertib [94]. Multiple
phase 1 studies establishing the safety and tolerability of
afuresertib, both as monotherapy and in combination
with other agents, have already been completed. In a
phase 1 trial of 73 patients treated with oral afuresertib,
toxicities proved relatively benign with the most fre-
quent adverse events being nausea (35.6 %), diarrhea
(32.9 %), and dyspepsia (24.7 %) and the dose-limiting
toxicity proving to be liver function test abnormalities
found in 2 patients treated at the highest investigated
dose [95]. Afuresertib has also demonstrated a favorable
safety profile when combined with bortezomib and dexa-
methasone in patients with relapsed/refractory MM in a
phase 1b trial which had enrolled 67 patients at the time
of last data cutoff [96]. This same trial has also prelimin-
arily demonstrated the significant clinical activity of the
combination with an ORR (based on serum M-protein
or free-light-chain levels) approaching 50 % in a popula-
tion of relapsed/refractory patients [96].
Bcl-2 inhibitors
ABT 199
Bcl-2 and its associated family of proteins are crucial
regulators of cell death. Bcl-2 itself is known to be an es-
sential anti-apoptotic protein and a rational target for
novel chemotherapeutic agents. Small molecule inhibi-
tors of the Bcl-2 family of proteins have been in the pre-
clinical stages of development for over a decade and,
after encouraging results, have been graduating to phase
1 clinical trials. Among the earliest such agents was
ABT-737, an inhibitor of the Bcl-2 family proteins Bcl-2,
Bcl-xL, and Bcl-w. In vitro studies conducted on malig-
nant cell lines showed ABT-737 to be highly effective in
indirectly inducing cancer cell apoptosis, and studies in
murine models demonstrated its ability to cause tumor
regression and promote survival. These preclinical results
were particularly impressive with regard to hematologic
malignancies [97]. Small molecule inhibitors of Bcl-2
family proteins, such as navitoclax and obatoclax,
have entered early-phase clinical trials, particularly for
their potential roles in small cell lung cancer. The
Bcl-2-specific agent ABT-199 has been under preclinical
investigation for hematologic malignancies with multiple
trials currently underway [98]. ABT-199 is the first in-
class orally bioavailable Bcl-2-specific small molecule in-
hibitor to be developed. Ex vivo studies of its use in
hematologic malignancies have been encouraging, and un-
like other agents in its class (ABT-737, navitoclax), it does
not appear to be associated with severe use limiting
thrombocytopenia [98]. Preclinical investigations into its
utility in MM have suggested therapeutic potential in cer-
tain subsets of patients. Myeloma cell lines particularly
dependent on Bcl-2 for survival are sensitive to ABT-199,
whereas cell lines dependent or co-dependent on other
Bcl-2 family proteins are less sensitive to Bcl-2 inhibitors
[99]. Interestingly, ABT-199 has demonstrated consider-
able ex vivo synergy with the novel proteasome inhibitor
carfilzomib, ostensibly because among carfilzomib’s mani-
fold mechanisms of action is induction of Noxa, a pro-
Naymagon and Abdul-Hay Journal of Hematology & Oncology  (2016) 9:52 Page 10 of 20
apoptotic member of the Bcl-2 family [99]. ABT-199 has
also been shown to be effective in cell lines of MMs with
t(11;14), and accordingly, Bcl-2 may thus be a promising
targeted therapy for this particular myeloma subtype [97].
ABT-199 therapy has thus far demonstrated significant
therapeutic activity in chronic lymphocytic leukemia and
non-Hodgkin lymphomas, and a phase 1 trial in relapsed
MM is ongoing [97]. The major dose-limiting toxicity in
clinical trials was tumor lysis syndrome (TLS). Preclinical
trials demonstrated that ABT-199 can induce rapid and
profound apoptosis of CLL cells, sometimes within only
8 h, and similar finding have been demonstrated in vivo.
The rate of significant TLS in CLL patients is 5 %, includ-
ing two deaths and one instance of acute renal failure.
Such rapid tumor lysis has not yet been observed in pre-
clinical studies with MM; however, as investigations tran-
sition to the clinical phase measures toward tumor lysis
prophylaxis may be warranted [100].
BTK inhibitors
Ibrutinib
Bruton’s tyrosine kinase (BTK) is an enzyme that plays a
crucial role in B cell survival and maturation. Ibrutinib,
an orally administered selective inhibitor of BTK, has
demonstrated impressive efficacy in the treatment of B
cell malignancies and is FDA approved as a therapy for
mantle cell lymphoma and chronic lymphocytic leukemia
[101, 102]. Ibrutinib, via the inhibition of BTK, has been
shown to interfere with intracellular B cell signaling as
well as with malignant B cells’ ability to interact with po-
tentially protective microenvironments. These effects limit
the malignant B cells’ survival ability and promote apop-
tosis [101]. Recent preclinical studies have demonstrated
that BTK may also be involved in the propagation and
maintenance of malignant plasma cell clones in MM [101,
103]. Expression of BTK in malignant plasma cells is in-
creased fourfold relative to benign controls and compar-
able to BTK expression in CLL and MCL [104]. BTK
expression has been shown to be markedly elevated and
activated in dexamethasone-resistant MM cell lines, a
shared single nucleotide polymorphism in the BTK gene
has been demonstrated in a subset of myeloma cell lines,
and patients with higher BTK expression in their malig-
nant plasma cells have been shown to have a worse prog-
nosis [101]. Ibrutinib has been shown to be cytotoxic to
malignant plasma cells in vitro, and treatment with ibruti-
nib has been shown to augment the cytotoxic activity of
bortezomib and lenalidomide. Ibrutinib activity in mye-
loma cells seems to be mediated by its ability to interfere
with the NF-kB-signaling pathway and thus promote
apoptosis [102]. Ibrutinib is presently being evaluated in a
phase 2 dose escalation study, as a single agent or in com-
bination with dexamethasone, in patients with relapsed or
refractory MM, with preliminary results demonstrating




Dinaciclib is a novel small molecule inhibitor of cyclin-
dependent kinases (CDKs), the ubiquitous protein ki-
nases central to the regulation of the cell cycle. Dinaci-
clib primarily inhibits CDK1, CDK2, CDK5, and CDK9
[105]. It has proven to be relatively well tolerated in ini-
tial phase 1 trials and has demonstrated clinical efficacy
in chronic lymphocytic leukemia and solid tumors [105].
Dinaciclib was investigated in a dose escalation trial as a
single agent for relapsed/refractory MM. Twenty-seven
patients with a median of four prior therapies were
treated with dinaciclib as a single agent. Three of the 27
(11 %) patients demonstrated a confirmed PR with 2 of
them demonstrating a very good PR, and an additional 2
patients demonstrated a minimal response (clinical benefit
rate was 19 %) [105]. CDK5 inhibition has been shown to
enhance the activity of proteasome inhibitors in vitro,
suggesting that a trial combination of dinaciclib and
bortezomib may yield fruitful results in the future [105].
IL-6 inhibitors
Siltuximab
Interleukin 6 has been shown to act as a survival factor
and growth factor for MM cells in preclinical studies.
Serum IL-6 concentration has been shown to correlate
with disease stage and prognosis in MM. Increased
concentrations of IL-6 in MM are thought to arise
from bone marrow stromal cells, and IL-6 is thought to
promote the survival of malignant plasma cells via interac-
tions with adhesion molecules, cytokines, tumor suppres-
sor genes, and oncogenes [106]. Siltuximab, a chimeric
monoclonal antibody which binds IL-6, has been approved
by the FDA for the treatment of multicentric Castleman’s
disease and is being investigated in MM [107]. A phase 2
randomized study comparing a bortezomib-melphalan-
prednisone regimen with and without siltuximab in 106
transplant-ineligible patients with newly diagnosed MM
was conducted. VGPR rate was significantly improved
with siltuximab compared to without (71 vs 51 %, p =
0.0382); however, the study failed to confirm its hypothesis
that the addition of siltuximab would improve the CR rate
by at least 10 % with a CR rate proved to be 27 % with sil-
tuximab versus 22 % without it. ORR was also not signifi-
cantly improved (88 % with siltuximab compared to 80 %
without). Median PFS was 17 months, and 1-year overall
survival was 88 % and both were identical in the 2 arms
[108]. Another phase 2 study, which was a randomized,
double-blind, placebo-controlled trial, was performed
comparing siltuximab and bortezomib versus bortezomib
alone in patients with relapsed/refractory MM. Two
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hundred eighty-one patients were randomized, and the
study failed to show that the addition of siltuximab to bor-
tezomib yields a significant improvement in PFS, or me-
dian overall survival, or ORR, or CR rate [107]. Siltuximab
is presently being studied in high-risk smoldering MM
and may have a future in that aspect and so far of unclear
significant in MM patients.
Kinesin spindle protein inhibitors
Filanesib (ARRY-520)
Kinesin spindle protein (KSP), a constituent of the kine-
sin class of microtubule-based proteins, plays a key role
in centrosome separation and bipolar spindle assembly
during mitosis. KSP is also believed to have anti-
apoptotic properties via mediation of the cell survival
protein myeloid leukemia sequence 1 (Mcl-1). Filanesib
is a KSP inhibitor with significant anti-tumor activity.
Among filanesib’s mechanisms of action is inhibition of
cell proliferation via preclusion of proper mitotic spindle
assembly. However, its most robust anti-myeloma prop-
erties seem to lie in its ability to promote apoptosis via
the degradation of Mcl-1. Proliferating hematopoietic
cells, including myeloma cells, are particularly dependent
on Mcl-1 and thus particularly sensitive to inhibition of
KSP. This principle underlies the study of KSP inhibitors
in the treatment of MM [109].
Phase 1 trials of filanesib in relapsed and refractory
MM, both as monotherapy and in combination with
various agents including dexamethasone, bortezomib,
and carfilzomib, have demonstrated its toxicities to be
largely hematologic [110, 111]. The dose-limiting toxicity
is neutropenia, which often requires granulocyte colony-
stimulating factor (G-CSF) support [109]. A number of
phase 1 trials demonstrated preliminary indications of
filanesib efficacy in MM. In a phase 1 study of filanesib,
bortezomib, dexamethasone, and prophylactic G-CSF in
relapsed/refractory patients revealed that 4 of 13 (31 %)
patients on high-dose filanesib/bortezomib demonstrate
a PR with significantly inferior results in the low-dose
cohort [110]. In a phase 1 trial of filanesib with carfilzo-
mib in 19 relapsed/refractory patients, the ORR was
58 % [111]. A phase 2 study investigating filanesib both
with and without low-dose dexamethasone in patients
refractory to both bortezomib and lenalidomide showed
that among the 32 patients treated with filanesib alone,
minor response was observed in 19 % and PR was ob-
served in 16 %. Among the 18 patients treated with fila-
nesib and low-dose dexamethasone, the ORR was 28 %
with 22 % demonstrating PR or greater [112]. Preclinical
studies have demonstrated that the acute phase protein
alpha-1 acid glycoprotein (AAG) can bind filanesib, re-
ducing the amount of free drug and possibly its treat-
ment effect [113]. This observation was taken into
account in a phase 2 trial of filanesib with and without
dexamethasone in relapsed/refractory patients. This
study included 2 patient cohorts: one double refractory
to both lenalidomide and bortezomib that was treated
with single-agent filanesib and another cohort triple re-
fractory to lenalidomide, bortezomib, and dexametha-
sone that was treated with filanesib in combination with
dexamethasone. Baseline plasma AAG levels were mea-
sured in both cohorts. Thirty-two patients were enrolled
in the double refractory cohort and 50 patients in the
triple refractory cohort. Patients in the triple refractory
cohort had more prior treatments and shorter times to
progression on most recent treatment on average. ORR
in both of these heavily pretreated cohorts was 16 %. Of
note, patients with high AAG demonstrate an ORR of
0 % and patients with low AAG demonstrated an ORR
(across both cohorts) of 24 % [111]. These studies sug-
gest that there may be a role for filanesib in the future
in combination therapy for patients with refractory MM
and low AAG.
PI3K inhibitors
The phosphoinositide 3-kinase (PI3K) family of enzymes
are a group of lipid kinase signal transducers involved in
a diverse array of cellular functions including growth,
proliferation, differentiation, and survival. Among the
various classes of PI3Ks, class 1 isoforms have proven to
be the major target in drug designs. Perifosine, a com-
bined PI3K and AKT inhibitor, was among the first PI3K
inhibitors to be investigated in clinical trials. Although it
initially displayed promise in the treatment of relapsed
and refractory MM, a phase 3 trial comparing perifosine,
bortezomib, and dexamethasone to bortezomib and
dexamethasone alone was discontinued in 2013 after
interim results showed that the addition of perifosine
had not, and likely would not, significantly extend
PFS. Another PI3K inhibitor, idelalisib, has proven
more successful in the treatment of hematologic ma-
lignancies. In 2014, idelalisib was approved for the
treatment of relapsed chronic lymphocytic leukemia
(CLL), small lymphocytic lymphoma (SLL), and follicular
lymphoma (FL) [114].
Numerous PI3K inhibitors are presently undergoing
preclinical investigation for their potential use in MM.
BAY80-6946, an inhibitor of PI3K-a has demonstrated
significant, dose-dependent, anti-tumoral effects across a
number of MM cell lines where it was shown to pro-
mote cell cycle arrest and apoptosis [115]. Notably,
BAY80-6946 was shown to interfere with the oncogenic
effects of insulin growth factor 1 (IGF-1). Another PI3K
inhibitor, GDC-0941, has also been shown to induce cell
cycle arrest and apoptosis in myeloma cell lines [116]. It
has shown significant synergy with lenalidomide and
dexamethasone in murine xenograft tumor models.
Buparlisib, an oral PI3K inhibitor with great promise in
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breast cancer and other solid malignancies, has also
demonstrated encouraging results in mouse models of
myeloma and, uniquely, has been shown to mediate a re-
duction in osteolytic lesions via downregulation of osteo-
clasts and upregulation of osteoblasts [117]. We must
await further studies to determine the potential of PI3K
inhibitors in the treatment of relapsed/refractory MM;
however, based on the preclinical data to date, and their
success in other malignancies, there seems to be a future
for their use in MM.
The role of novel agents in emerging treatment
paradigms
A decade ago, the introduction of bortezomib and lenali-
domide revolutionized the therapeutic approach to MM
and established a new front line for treatment of the dis-
ease. Today, these agents remain at the backbone of ini-
tial treatment regimens such as cyclophosphamide/
bortezomib/dexamethasone (CyBorD) and lenalidomide/
bortezomib/dexamethasone (RVD) [26, 27]. Neverthe-
less, in spite of the advancements offered by bortezomib
and lenalidomide, the natural course of MM often re-
mains one of relapse and progressive refractoriness [33].
Although bortezomib- and lenalidomide-based regimens
have proven effective in relapsed disease, repeatedly re-
lapsed or high-risk clones can and do become refractory
to one or both of these agents [34, 35]. There is thus
great interest in developing new agents which remain ef-
fective in patients refractory to conventional therapy,
agents which may be tapped once the front line has been
exhausted. There have been six such agents approved
for use in relapsed/refractory MM since 2012, four of
which have been approved since 2015.
Among the most promising of these agents include
novel proteasome inhibitors and immunomodulators
which intuitively build upon the progress made by their
predecessors, bortezomib and lenalidomide, respectively.
The first of this new generation of agents to receive
FDA approval was the novel immunomodulator pomali-
domide (Pomalyst) which demonstrated impressive effi-
cacy in cases refractory to lenalidomide, bortezomib, or
both [37, 38, 42]. As such pomalidomide is approved for
use, alone or in combination with dexamethasone, in re-
lapsed/refractory MM patients who have received at
least two prior therapies including lenalidomide and bor-
tezomib and have demonstrated disease progression
within 60 days of their most recent treatment [41]. The
approval of pomalidomide was closely followed by the
approval of two novel proteasome inhibitors, carfilzomib
(Kyprolis) and ixazomib (Ninlaro). On the strength of
the ASPIRE trial, carfilzomib (in combination with lena-
lidomide and dexamethasone) gained approval for the
treatment of patients with relapsed MM who have re-
ceived one to three prior lines of therapy [45]. The
effectiveness of carfilzomib was underscored by the EN-
DEAVOR trial in which carfilzomib demonstrated clear
clinical superiority to its predecessor bortezomib with
regard to the primary endpoint of PFS [45, 47]. Ixazomib
earned its approval largely on the strength of the
TOURMALINE-MM1 trial where it demonstrated sig-
nificant efficacy in combination with lenalidomide and
dexamethasone [54]. Ixazomib is approved (in combin-
ation with lenalidomide and dexamethasone) to treat pa-
tients who have received at least one prior therapy.
Pomalidomide, carfilzomib, and ixazomib offer effective
options for relapsed patients who have developed refrac-
toriness to lenalidomide and bortezomib. For the time
being, these novel agents remain “second line”; however,
trials such as ENDEAVOR suggest that they may soon
play a role on the front line of treatment, especially
among high-risk patients. The most effective combina-
tions of these agents among each other, with other novel
agents, and with established frontline agents, are yet to
be determined and will likely be the subject of numerous
forthcoming trials.
Histone deacetylase inhibitors offer a novel mechan-
ism for MM therapy. Panobinostat (Farydak) remains
the first and only drug in this class to have received
FDA approval. Largely on the strength of the PANO-
RAMA trials, panobinostat (in combination with bortezo-
mib and dexamethasone) has been approved for the
treatment of patients who have received at least two prior
standard therapies (including bortezomib and an immu-
nomodulatory agent) [76, 77]. Panobinostat is an effective
agent for the treatment of relapsed/refractory disease, and
its novel mechanism of action makes it a promising com-
ponent in combination regimens. To date, it is only ap-
proved for combination use with bortezomib; however, we
expect future trials to establish its utility in combination
with immunomodulators and other novel agents especially
carfilzomib.
Among the most exciting areas of progress in mye-
loma therapy is the development of novel monoclonal
antibodies, two of which are now approved for use in
relapsed/refractory disease. Daratumumab (Darzalex),
a monoclonal antibody targeting CD38, recently re-
ceived accelerated approval as monotherapy for use in
patients who have received at least three prior lines
of treatment [67]. In the same month, elotuzumab
(Empliciti), a monoclonal antibody targeting the cell
surface glycoprotein CS1, received approval for use
(in combination with lenalidomide and dexamethasone)
in patients who have received one to three prior therapies.
Elotuzumab was granted breakthrough therapy designa-
tion largely on the strength of the ELOQUENT 2 trial
[65, 69]. Daratumumab and elotuzumab signal the emer-
gence of monoclonal antibodies as central agents in the
treatment of MM, and numerous other antibodies with
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Table 1 Novel agents in the treatment of multiple myeloma
Category Agent Stage of development Major trials (All trials in relapsed/refractory pts unless
otherwise stated)
Major trials (All trials in relapsed/refractory pts unless
otherwise stated)
Adverse events (Grade 3/4 only unless otherwise stated)
Adverse events (Grade 3/4 only unless otherwise stated)
AKT inhibitors Afuresertib Phase 1 clinical trials *Afuresertib monotherapy in 34 pts, PR 9 %, MR 9 % [95] *Nausea (35.6 %), diarrhea (32.9 %), dyspepsia (24.7 %) [95]
Alkylating agents Bendamustine Phase 2 clinical trials *Bendamustine-lenalidomide-dexamethasone in 29 pts,
1-year OS 93 %, 1-year PFS 20 % [90]
*Bendamustine-bortezomib-dexamethasone in 79 pts,
OR 60.8 %. PFS 9.7 months, OS 25.6 months [91]
*Bendamustine-lenalidomide-dexamethasone in 29 pts,
1-year OS 93 %, 1-year PFS 20 % [90]
*Bendamustine-bortezomib-dexamethasone in 79 pts,
OR 60.8 %. PFS 9.7 months, OS 25.6 months [91]
*Neutropenia (62 %), thrombocytopenia (38 %), leukopenia
(38 %) [90]
*Thrombocytopenia (38 %), infections (23 %), polyneuropathy
(grade 4) (7 %), polyneuropathy (52 %) [91]
*Neutropenia (62 %), thrombocytopenia (38 %), leukopenia
(38 %) [90]
*Thrombocytopenia (38 %), infections (23 %), polyneuropathy
(grade 4) (7 %), polyneuropathy (52 %) [91]
Bcl-2 inhibitors ABT 199 Preclinical studies N/A N/A
BTK inhibitors Ibrutinib Phase 1/2 clinical trials *Ibrutinib single agent or in combination with
dexamethasone, trial ongoing [104]
*Trial ongoing [104]
CDK inhibitors Dinaciclib Phase 1/2 clinical trials *Dinaciclib monotherapy in 27 pts, PR 11 %, CBR 19 %
[105]
*Diarrhea (87 %), fatigue (67 %), neutropenia (27 %) [105]
Histone deacetylase
inhibitors
Panobinostat Phase 3 clinical trials Postmarketing
surveillance
Phase 3 clinical trials Postmarketing
surveillance
*PANORAMA 2: panobinostat-bortezomib-dexamethasone
in 55 pts, OR 34.5 %, CBR 52.7 %, PFS 5.4 months [76]
*PANORAMA 1: 768 pts randomized to bortezomib-
dexamethasone with either panobinostat or placebo.
PFS panobinostat group 12 months, PFS placebo group
8.1 months (HR 0.63) [77]
*PANORAMA 2: panobinostat-bortezomib-dexamethasone
in 55 pts, OR 34.5 %, CBR 52.7 %, PFS 5.4 months [76]
*PANORAMA 1: 768 pts randomized to bortezomib-
dexamethasone with either panobinostat or placebo.
PFS panobinostat group 12 months, PFS placebo group
8.1 months (HR 0.63) [77]
*Thrombocytopenia (64 %), fatigue (20 %), diarrhea (20 %) [76]
*Thrombocytopenia (67 vs 31 %), neutropenia (35 vs 11 %),
diarrhea (26 vs 8 %) [77]
*Thrombocytopenia (64 %), fatigue (20 %), diarrhea (20 %) [76]
*Thrombocytopenia (67 vs 31 %), neutropenia (35 vs 11 %),
diarrhea (26 vs 8 %) [77]
Ricolinostat Preclinical studies N/A N/A
Vorinostat Phase 3 clinical trials *VANTAGE 095: vorinostat-bortezomib in 143 pts (all
bortezomib refractory), OR 17 %, CBR 31 % [85]
*VANTAGE 088: 637 pts randomized to bortezomib-
vorinostat or bortezomib-placebo. PFS vorinostat
group 7.63 months, PFS placebo group 6.83 months,
p = 0.01 [81]
*VANTAGE 095: vorinostat-bortezomib in 143 pts
(all bortezomib refractory), OR 17 %, CBR 31 % [85]
*VANTAGE 088: 637 pts randomized to bortezomib-
vorinostat or bortezomib-placebo. PFS vorinostat
group 7.63 months, PFS placebo group 6.83 months,
p = 0.01 [81]
*Thrombocytopenia (67 %), anemia (38 %), neutropenia
(32 %) [85]
*Thrombocytopenia (45 vs 24 %), neutropenia (28 vs 25 %),
anemia (17 vs 13 %) [81]
*Thrombocytopenia (67 %), anemia (38 %), neutropenia
(32 %) [85]
*Thrombocytopenia (45 vs 24 %), neutropenia (28 vs 25 %),
anemia (17 vs 13 %) [81]
IL-6 inhibitors Siltuximab Phase 2 clinical trials *106 pts randomized to bortezomib-melphalan-
prednisone with vs without siltuximab. OR 88 vs
80 %, VGPR 71 vs 51 %, (p = 0.0382). Median PFS
*Neutropenia (62 vs 43 %), thrombocytopenia (44 vs 25 %),
pneumonia (17 vs 17 %) [108]
*Neutropenia (49 vs 29 %), thrombocytopenia (48 vs 34 %),




















Table 1 Novel agents in the treatment of multiple myeloma (Continued)
(17 months) and 1-year OS (88 %) identical across
both arms [108]
*281 pts randomized to bortezomib with siltuximab
vs placebo. PFS 8.0 vs 7.6 months (HR 0.869,
p = 0.345). OR 55 VS 47 % (p = 0.213) [107]
*106 pts randomized to bortezomib-melphalan-
prednisone with vs without siltuximab. OR 88 vs
80 %, VGPR 71 vs 51 %, (p = 0.0382). Median PFS
(17 months) and 1-year OS (88 %) identical across
both arms [108]
*281 pts randomized to bortezomib with siltuximab
vs placebo. PFS 8.0 vs 7.6 months (HR 0.869, p = 0.345).
OR 55 VS 47 % (p = 0.213) [107]
*Neutropenia (62 vs 43 %), thrombocytopenia (44 vs 25 %),
pneumonia (17 vs 17 %) [108]
*Neutropenia (49 vs 29 %), thrombocytopenia (48 vs 34 %),
all-grade infections (62 vs 49 %) [107]
Immunomodulators Pomalidomide Phase 2 clinical trials Postmarketing
surveillance
Phase 2 clinical trials Postmarketing
surveillance
*Pomalidomide and dexamethasone in 60 pts.
OR 63 %, PFS 11.6 months [37]
*Pomalidomide and dexamethasone in 84 pts.
OR 35 %, OS 14.9 months, 18-month OS 44 % [39]
*Pomalidomide and dexamethasone in 60 pts.
OR 63 %, PFS 11.6 months [37]
*Pomalidomide and dexamethasone in 84 pts.
OR 35 %, OS 14.9 months, 18-month OS 44 % [39]
*Neutropenia (32 %), anemia (5 %), thromboembolism
(2 %) [37]
*Neutropenia (62 %), anemia (36 %), infections (23 %) [39]
*Neutropenia (32 %), anemia (5 %), thromboembolism
(2 %) [37]
*Neutropenia (62 %), anemia (36 %), infections (23 %) [39]
KSP inhibitors Filanesib Phase 2 clinical trials *Filanesib with and without low-dose dexamethasone
in 82 pts. OR 16 % in both cohorts. Among pts with
high and low serum AAG, OR was 0 % and 24 %
respectively across both cohorts [111]
*Thrombocytopenia (44 vs 42 %), anemia (38 vs 50 %),
neutropenia (38 vs 38 %) [111]
Monoclonal
antibodies
Daratumumab Phase 2 clinical trials
Postmarketing surveillance
*Daratumumab monotherapy in 106 pts. OR 29.2 %,
1-year OS 65 % [65]
*Anemia (33.0 %), thrombocytopenia (26 %), neutropenia
(22.6 %) [65]
Elotuzumab Phase 3 clinical trials
Postmarketing Surveillance
*ELOQUENT 2: 646 pts randomized to lenalidomide-
dexamethasone with and without elotuzumab.
OR 79 vs 66 %(p < 0.001). PFS 19.4 vs 14.8 months,
HR 0.70 (CI 0.57 to 0.85, p < 0.001) [70]
*Lymphocytopenia (77 vs 49 %), anemia (19 vs 21 %),
thrombocytopenia (19 vs 20 %) [70]
Indatuximab Phase 1/2 clinical trials *Indatuximab-lenalidomide-dexamethasone in
15 pts. OR 78 % [72]
*Hypokalemia, fatigue, diarrhea reported as “most common
adverse events” [72]
SAR650984 Phase 1 clinical trials *SAR650984 monotherapy in 35 pts. ORR 33 %,
CR 11 % [73]
*SAR650984 and lenalidomide in 31 pts. ORR
64.5 %, CBR 71 % [74]
*Pneumonia 9 % [73]
*Fatigue (41.9 %), nausea (38.7 %), upper respiratory tract
infection (38.7 %), and diarrhea (35.5 %) [74]
PI3K inhibitors Numerous
agents
Preclinical studies N/A N/A
Proteasome inhibitors Carfilzomib Phase 3 clinical trials Postmarketing
surveillance
*ASPIRE: 792 pts randomized to lenalidomide-
dexamethasone with and without carfilzomib.
PFS 26.3 vs 17.6 months, HR 0.69, p = 0.0001.
OR 87.1 vs 66.7 %, CR 31.8 vs 9.3 % [45]
*ENDEAVOR: 929 pts randomized to carfilzomib/
dexamethasone vs bortezomib/dexamethasone.
PFS 18.7 vs 9.4 months, HR 0.53, CI 0.44 - 0.65,
p = 0.0001. Complete results pending [46], [47]
*Hypokalemia (9.4 vs 4.9 %), fatigue (7.7 vs 6.4 %),
hypertension (4.3 vs 1.8 %) [45]




















Table 1 Novel agents in the treatment of multiple myeloma (Continued)
Ixazomib Phase 3 clinical trials
Postmarketing surveillance
*TOURMALINE-MM1:722 pts randomized to
lenalidomide and dexamethasone with and
without ixazomib. PFS 20.6 vs 14.7 months
(p = 0.012), OR 78 % (median duration
21 months) vs 72 % (median duration
15 months) [54]
*“Most common events” included neutropenia, anemia,
thrombocytopenia, and pneumonia [54]
Marizomib Phase 1 clinical trials *Marizomib monotherapy in 15 pts.
PR 20 %, CBR 57 % [56]
*Fatigue, gastrointestinal AEs, dizziness, and headache
reported as “most common adverse events” [56]
Oprozomib Phase 1 clinical trials *Oprozomib-dexamethasone in 29 pts. OR
33.3 %, CBR 46.7 % [59]





















various targets are present in the pipeline. As with
the above agents, the role of these monoclonal anti-
bodies remains limited to relapsed/refractory disease,
and the most effective combination regimens remain
to be established.
The emergence of this new generation of novel agents
offers many options for the treatment of relapsed/refrac-
tory MM. Cases refractory to lenalidomide, bortezomib,
or both can now be treated in several possible ways such
as with novel immunomodulators, novel proteasome in-
hibitors, HDCA inhibitors, or monoclonal antibodies.
The choice of which novel agent to use is not yet subject
to a rigid paradigm and is decided on a case by case
basis, with thought given to the nature of the preceding
line(s) of treatment, availability, cost, and tolerability. As
the optimal combinations of these regimens are not yet
established, enrollment in clinical trials, where many of
these agents are being evaluated as components of novel
regimens, will be the future to pave the way to know the
best effective treatment.
Conclusions
We are in a new era in the treatment of MM where we
have newer and better agents than we did just 1 year
ago. We have at our disposable more effective treatments
and a plethora of novel weapons to target even the
toughest relapsed/refractory cases. Successful outcomes
are more likely to be achieved with combinations of estab-
lished agents and the novel agents discussed in this review
(Table 1). The future of MM treatment is encouraging and
promises better response rates and improved survival
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